BioSpace News Archive

Invicro LLC, a Konica Minolta company announces that the paper, TauIQ - A canonical image-based algorithm to quantify tau PET scans, will be published in The Journal of Nuclear Medicine (JNM). In conjunction with this publication, Invicro has launched 21 CFR Part 11 compliant TauIQ services in its Core Lab as part of its expanded IQ-Analytics Platform, which includes AmyloidIQ and DaTIQ.

Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the fourth quarter and fiscal year 2020 after the stock market close on Tuesday, February 16, 2021

Today, LGC announced the acquisition of Technopath Clinical Diagnostics, a global leader in the development and manufacture of quality control (QC) solutions for clinical laboratories.

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced the launch of next-generation hardware and software for its ExactechGPS® guided personalized surgery system.

The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on January 29, 2021, the Company granted stock options and restricted stock units to 92 new employees of the Company.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Cytokinetics, Incorporated announced that on January 29, 2021 it granted stock options to purchase an aggregate of 13,500 shares of common stock to Cinzia Ellero, a new employee whose employment commenced in January 2021 as a material inducement to her employment.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share, before deducting underwriting discounts and commissions